In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Olema Pharmaceuticals (OLMA – Research Report), with a price target of $27.00.
Sam Slutsky has given his Buy rating due to a combination of factors related to Olema Pharmaceuticals’ strategic positioning in the ER+ breast cancer treatment landscape. The company’s lead candidate, palazestrant (OP-1250), is being tested in a Phase 3 trial as a monotherapy for advanced/metastatic ER+ breast cancer, and recent data from competitors in similar settings suggest potential positive readthrough for Olema’s ongoing trials.
Additionally, Olema’s management has been proactive in aligning their development strategy with upcoming readouts from other pharmaceutical companies, which could further validate their approach. The company’s financial health, with approximately three years of cash runway, supports continued development efforts. These factors combined suggest a promising outlook for Olema, justifying the Buy rating.
According to TipRanks, Slutsky is an analyst with an average return of -11.8% and a 29.03% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Immunovant, Olema Pharmaceuticals, and Astria Therapeutics.